

CLNE0020: Motoneurons, Neuromuscular Junctions and Associated Disease

View Online



1.

Morren JA, Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. *Expert Opinion on Investigational Drugs*. 2012;21(3):297-320. doi:10.1517/13543784.2012.657303

2.

Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? *The Lancet Neurology*. 2014;13(11):1127-1138. doi:10.1016/S1474-4422(14)70129-2

3.

Maragakis NJ. What can we learn from the edaravone development program for ALS? *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2017;18(sup1):98-103. doi:10.1080/21678421.2017.1361446

4.

Hughes J, Rees S, Kalindjian S, Philpott K. Principles of early drug discovery. *British Journal of Pharmacology*. 2011;162(6):1239-1249. doi:10.1111/j.1476-5381.2010.01127.x

5.

Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *The Lancet Neurology*. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3

6.

Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *The Lancet Neurology*. 2018;17(4):347-361. doi:10.1016/S1474-4422(18)30025-5

7.

Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. *The Lancet Neurology*. 2018;17(5):445-455. doi:10.1016/S1474-4422(18)30026-7

8.

Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscular Disorders*. 2018;28(2):103-115. doi:10.1016/j.nmd.2017.11.005

9.

Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscular Disorders*. 2018;28(3):197-207. doi:10.1016/j.nmd.2017.11.004

10.

Scoto M, Finkel RS, Mercuri E, Muntoni F. Therapeutic approaches for spinal muscular atrophy (SMA). *Gene Therapy*. 2017;24(9):514-519. doi:10.1038/gt.2017.45

11.

Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. *PLOS ONE*. 2017;12(2). doi:10.1371/journal.pone.0172346

12.

Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. *Muscle & Nerve*. 2017;55(6):869-874. doi:10.1002/mus.25430

13.

Westerberg E, Molin CJ, Spörndly Nees S, Widenfalk J, Punga AR. The impact of physical exercise on neuromuscular function in Myasthenia gravis patients. *Medicine*. 2018;97(31). doi:10.1097/MD.0000000000011510

14.

Peragallo JH. Pediatric Myasthenia Gravis. *Seminars in Pediatric Neurology*. 2017;24(2):116-121. doi:10.1016/j.spen.2017.04.003

15.

Laurá M, Singh D, Ramdharry G, et al. Prevalence and orthopedic management of foot and ankle deformities in Charcot-Marie-Tooth disease. *Muscle & Nerve*. 2018;57(2):255-259. doi:10.1002/mus.25724

16.

Reilly MM, Pareyson D, Burns J, et al. 221st ENMC International Workshop: Neuromuscular Disorders. 2017;27(12):1138-1142. doi:10.1016/j.nmd.2017.09.005

17.

Ramdharry GM, Pollard A, Anderson C, et al. A pilot study of proximal strength training in Charcot-Marie-Tooth disease. *Journal of the Peripheral Nervous System*. 2014;19(4):328-332. doi:10.1111/jns.12100

18.

Gibson S, Haringer V. Amyotrophic lateral sclerosis: clinical perspectives. *Orphan Drugs: Research and Reviews*. Published online April 2015. doi:10.2147/ODRR.S63585

19.

Berlowitz DJ, Howard ME, Fiore JF, et al. Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016;87(3):280-286. doi:10.1136/jnnp-2014-310055

20.

Harwood CA, McDermott CJ, Shaw PJ. Clinical aspects of motor neurone disease. *Medicine*. 2012;40(10):540-545. doi:10.1016/j.mpmed.2012.07.003

21.

Drory VE, Goltsman E, Goldman Reznik J, Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. *Journal of the Neurological Sciences*. 2001;191(1-2):133-137. doi:10.1016/S0022-510X(01)00610-4

22.

Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. *Nature Reviews Neurology*. 2017;13(2):96-104. doi:10.1038/nrneurol.2016.182

23.

Carrì MT, D'Ambrosi N, Cozzolino M. Pathways to mitochondrial dysfunction in ALS pathogenesis. *Biochemical and Biophysical Research Communications*. 2017;483(4):1187-1193. doi:10.1016/j.bbrc.2016.07.055

24.

Lin G, Mao D, Bellen HJ. Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload. In: *Fly Models of Human Diseases*. Vol 121. Elsevier; 2017:111-171. doi:10.1016/bs.ctdb.2016.07.004

25.

Monahan Z, Shewmaker F, Pandey UB. Stress granules at the intersection of autophagy and ALS. *Brain Research*. 2016;1649:189-200. doi:10.1016/j.brainres.2016.05.022

26.

Ruegsegger C, Saxena S. Proteostasis impairment in ALS. *Brain Research*. 2016;1648:571-579. doi:10.1016/j.brainres.2016.03.032

27.

Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. *Nature Neuroscience*. 2014;17(1):17-23. doi:10.1038/nn.3584

28.

Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nature Reviews Genetics*. 2000;1(1):20-29. doi:10.1038/35049541

29.

Harland R. Neural induction. *Current Opinion in Genetics & Development*. 2000;10(4):357-362. doi:10.1016/S0959-437X(00)00096-4

30.

Dasen JS, Jessell TM. Chapter Six Hox Networks and the Origins of Motor Neuron Diversity. In: *Hox Genes*. Vol 88. Elsevier; 2009:169-200. doi:10.1016/S0070-2153(09)88006-X

31.

Bonanomi D, Pfaff SL. Motor Axon Pathfinding. *Cold Spring Harbor Perspectives in Biology*. 2010;2(3):a001735-a001735. doi:10.1101/cshperspect.a001735

32.

Darabid H, Perez-Gonzalez AP, Robitaille R. Neuromuscular synaptogenesis: coordinating partners with multiple functions. *Nature Reviews Neuroscience*. 2014;15(11):703-718. doi:10.1038/nrn3821

33.

Kanning KC, Kaplan A, Henderson CE. Motor Neuron Diversity in Development and Disease. *Annual Review of Neuroscience*. 2010;33(1):409-440. doi:10.1146/annurev.neuro.051508.135722

34.

Ladle DR, Pecho-Vrieseling E, Arber S. Assembly of Motor Circuits in the Spinal Cord: Driven to Function by Genetic and Experience-Dependent Mechanisms. *Neuron*. 2007;56(2):270-283. doi:10.1016/j.neuron.2007.09.026

35.

Brownstone RM, Bui TV. Spinal interneurons providing input to the final common path during locomotion. In: *Breathe, Walk and Chew: The Neural Challenge: Part I*. Vol 187. Elsevier; 2010:81-95. doi:10.1016/B978-0-444-53613-6.00006-X

36.

Li L, Xiong WC, Mei L. Neuromuscular Junction Formation, Aging, and Disorders. *Annual Review of Physiology*. 2018;80(1):159-188. doi:10.1146/annurev-physiol-022516-034255

37.

Singhal N, Martin PT. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. *Developmental Neurobiology*. 2011;71(11):982-1005. doi:10.1002/dneu.20953

38.

Nishimune H, Valdez G, Jarad G, et al. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. *The Journal of Cell Biology*. 2008;182(6):1201-1215. doi:10.1083/jcb.200805095

39.

Rudolf R, Khan MM, Labeit S, Deschenes MR. Degeneration of Neuromuscular Junction in Age and Dystrophy. *Frontiers in Aging Neuroscience*. 2014;6.
doi:10.3389/fnagi.2014.00099

40.

Jones RA, Harrison C, Eaton SL, et al. Cellular and Molecular Anatomy of the Human Neuromuscular Junction. *Cell Reports*. 2017;21(9):2348-2356.
doi:10.1016/j.celrep.2017.11.008

41.

O'Connor E, Töpf A, Zahedi RP, et al. Clinical and research strategies for limb-girdle congenital myasthenic syndromes. *Annals of the New York Academy of Sciences*. 2018;1412(1):102-112. doi:10.1111/nyas.13520

42.

Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. *The Lancet Neurology*. 2015;14(4):420-434.
doi:10.1016/S1474-4422(14)70201-7

43.

Cruz PMR, Palace J, Beeson D. Congenital myasthenic syndromes and the neuromuscular junction. *Current Opinion in Neurology*. 2014;27(5):566-575.
doi:10.1097/WCO.0000000000000134

44.

Rodríguez Cruz PM, Palace J, Beeson D. Inherited disorders of the neuromuscular junction: an update. *Journal of Neurology*. 2014;261(11):2234-2243.
doi:10.1007/s00415-014-7520-7

45.

Belaya K, Rodríguez Cruz PM, Liu WW, et al. Mutations in *CHRNA1* cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. *Brain*. 2015;138(9):2493-2504. doi:10.1093/brain/awv185

46.

Rodríguez Cruz PM, Sewry C, Beeson D, et al. Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature. *Neuromuscular Disorders*. 2014;24(12):1103-1110. doi:10.1016/j.nmd.2014.07.005

47.

Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. *Nature Reviews Neuroscience*. 2016;17(2):103-117. doi:10.1038/nrn.2015.27

48.

Gilhus NE. Myasthenia Gravis. *New England Journal of Medicine*. 2016;375(26):2570-2581. doi:10.1056/NEJMra1602678

49.

Kusner LL, Kaminski HJ. Myasthenia Gravis. In: *Neurobiology of Brain Disorders*. Elsevier; 2015:135-150. doi:10.1016/B978-0-12-398270-4.00010-0

50.

Leung DG. Other Proven and Putative Autoimmune Disorders of the Peripheral Nervous System. Vol 1. Oxford University Press; 2017. doi:10.1093/med/9780199937837.003.0098

51.

Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010;81(8):850-857. doi:10.1136/jnnp.2008.169367

52.

Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. *The Lancet Neurology*. 2009;8(5):475-490.
doi:10.1016/S1474-4422(09)70063-8

53.

Spillane J, Ermolyuk Y, Cano-Jaimez M, et al. Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca²⁺ channels. *Neurology*. 2015;84(6):575-579.
doi:10.1212/WNL.0000000000001225

54.

Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. *New England Journal of Medicine*. 2016;375(6):511-522.
doi:10.1056/NEJMoa1602489

55.

Orrell, Richard WBarclay, Chris. Diagnosis and management of motor neurone disease. *Practitioner*. 260:17-21.
<https://search.proquest.com/docview/1844334383/64C39DCAF3D346C0PQ/1?accountid=14511>

56.

Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. *British Medical Bulletin*. 2016;119(1):87-98. doi:10.1093/bmb/ldw026

57.

Fuller G, Manford M. *Neurology: An Illustrated Colour Text*. 3rd ed. Churchill Livingstone Elsevier; 2010.
http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3669595080004761&institutionId=4761&customerId=4760

58.

Motor neurone disease: assessment and management | Guidance and guidelines | NICE.
<https://www.nice.org.uk/guidance/ng42>

59.

Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. *Revue Neurologique*. 2016;172(1):37-45. doi:10.1016/j.neurol.2015.11.002

60.

Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. *Amyotrophic Lateral Sclerosis*. 2012;13(1):1-10. doi:10.3109/17482968.2011.627589

61.

Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology*. 2015;84(22):2247-2257. doi:10.1212/WNL.0000000000001642

62.

Benatar M, Boylan K, Jeromin A, et al. ALS biomarkers for therapy development: State of the field and future directions. *Muscle & Nerve*. 2016;53(2):169-182. doi:10.1002/mus.24979

63.

Andreasson U, Blennow K, Zetterberg H. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2016;3:98-102. doi:10.1016/j.dadm.2016.05.005

64.

Gendron TF, Chew J, Stankowski JN, et al. Poly(GP) proteins are a useful pharmacodynamic marker for *Progranulin*-associated amyotrophic lateral sclerosis. *Science Translational Medicine*. 2017;9(383). doi:10.1126/scitranslmed.aai7866

65.

Vincent A. Unravelling the pathogenesis of myasthenia gravis. *Nature Reviews Immunology*. 2002;2(10):797-804. doi:10.1038/nri916

66.

Jacobson L, Polizzi A, Morriss-Kay G, Vincent A. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. *Journal of Clinical Investigation*. 1999;103(7):1031-1038. doi:10.1172/JCI5943

67.

Viegas S, Jacobson L, Waters P, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. *Experimental Neurology*. 2012;234(2):506-512. doi:10.1016/j.expneurol.2012.01.025

68.

Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. *Journal of Anatomy*. 2014;224(1):29-35. doi:10.1111/joa.12034

69.

Koneczny I, Cossins J, Waters P, Beeson D, Vincent A. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. *PLoS ONE*. 2013;8(11). doi:10.1371/journal.pone.0080695

70.

Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. *Nature Reviews Neuroscience*. 2016;17(2):103-117. doi:10.1038/nrn.2015.27

71.

Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry*. 2016;138:6-31. doi:10.1111/jnc.13654

72.

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry*. 2016;138:193-210. doi:10.1111/jnc.13656

73.

Volume 58, Issue 3, March 2016. Volume 58, Issue 3, March 2016. <https://link.springer.com/journal/12031/58/3>

74.

Badders NM, Korff A, Miranda HC, et al. Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy. *Nature Medicine*. 2018;24(4):427-437. doi:10.1038/nm.4500

75.

Beitel LK, Alvarado C, Mokhtar S, Paliouras M, Trifiro M. Mechanisms Mediating Spinal and Bulbar Muscular Atrophy: Investigations into Polyglutamine-Expanded Androgen Receptor Function and Dysfunction. *Frontiers in Neurology*. 2013;4. doi:10.3389/fneur.2013.00053

76.

Cortes CJ, Ling SC, Guo LT, et al. Muscle Expression of Mutant Androgen Receptor Accounts for Systemic and Motor Neuron Disease Phenotypes in Spinal and Bulbar Muscular Atrophy. *Neuron*. 2014;82(2):295-307. doi:10.1016/j.neuron.2014.03.001

77.

Fratia P, Nirmalanathan N, Masset L, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy. *Neurology*. 2014;82(23):2077-2084. doi:10.1212/WNL.0000000000000507

78.

Lieberman AP, Yu Z, Murray S, et al. Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy. *Cell Reports*. 2014;7(3):774-784. doi:10.1016/j.celrep.2014.02.008

79.

Malik B, Nirmalanathan N, Bilisland LG, et al. Absence of disturbed axonal transport in spinal and bulbar muscular atrophy. *Human Molecular Genetics*. 2011;20(9):1776-1786. doi:10.1093/hmg/ddr061

80.

Malik B, Nirmalanathan N, Gray AL, La Spada AR, Hanna MG, Greensmith L. Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. *Brain*. 2013;136(3):926-943. doi:10.1093/brain/aws343

81.

Manzano R, Sorarú G, Grunseich C, et al. Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease. *Journal of Neurology, Neurosurgery & Psychiatry*. 2018;89(8):808-812. doi:10.1136/jnnp-2017-316961

82.

Milioto C, Malena A, Maino E, et al. Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes. *Scientific Reports*. 2017;7(1). doi:10.1038/srep41046